Anticardiolipin and anti-β2 glycoprotein I antibody concentrations in patients with type 2 diabetes mellitus
Authors:
- Abdullah HacıhanefioğluAHAbdullah Hacıhanefioğlu
- Pınar TarkunPTPınar Tarkun
- Berrin ÇetinarslanBÇBerrin Çetinarslan
- Zeynep CantürkZCZeynep Cantürk
- 30 June 2005
- journal article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 68 (3) , 181-187
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Antiphospholipid antibodies: are they pro-atherogenic or an epiphenomenon of atherosclerosis?Immunobiology, 2003
- Qualitative and quantitative studies of autoantibodies to phospholipids in diabetes mellitusClinical and Experimental Immunology, 1999
- The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis.Journal of Clinical Investigation, 1998
- Phospholipid Binding Plasma Proteins Required for Antiphospholipid Antibody Detection—An OverviewAmerican Journal of Reproductive Immunology, 1997
- A Phospholipid-β2-Glycoprotein I Complex Is an Antigen for Anticardiolipin Antibodies Occurring in Autoimmune Disease But Not with InfectionLupus, 1992
- Pathogenesis of diabetic microangiopathy: An overviewThe American Journal of Medicine, 1991
- Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactorThe Lancet, 1990
- Anticardiolipin antibody levels in diabetic subjects with and without coronary artery diseasePostgraduate Medical Journal, 1989
- β2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregationAtherosclerosis, 1987
- Low functional and high antigenic antithrombin iii level in a patient with the lupus anticoagulant and recurrent thrombosisArthritis & Rheumatism, 1981